BeiGene, Ltd. — Form 10-Q Summary
Reporting period: Quarter and six months ended June 30, 2021. Amounts are U.S. dollars; financial statements are unaudited. The filing identifies the registrant as BeiGene, Ltd.
Business context
BeiGene is a commercial-stage biotechnology company developing and selling cancer medicines, with operations spanning China, the United States and other markets. Its products include internally developed BRUKINSA, tislelizumab and pamiparib, as well as licensed medicines. It reported more than 45 medicines and candidates in commercial or clinical development and approximately 6,400 employees.
Financial performance and liquidity
- Second-quarter revenue: $150.0 million, up 128.5% year over year. Product revenue was $138.6 million, up 111.2%; collaboration revenue was $11.4 million.
- Second-quarter product mix: Tislelizumab $74.9 million and BRUKINSA $42.4 million led sales. Product cost of sales was $36.3 million; product gross margin was 73.8%, versus 78.2% a year earlier.
- Second-quarter results: Operating loss was $474.8 million and net loss was $480.3 million, compared with net loss of $336.3 million in the prior-year quarter. Loss per ADS was $5.23.
- First-half results: Revenue was $755.9 million, including $511.1 million of Novartis collaboration revenue; net loss was $413.8 million versus $701.3 million a year earlier. The half-year comparison includes $484.6 million of license revenue recognized under the Novartis agreement. BeiGene reported a $66.5 million profit for first-quarter 2021 in its equity statement, followed by the second-quarter loss.
- First-half expenses and margins: R&D expense was $676.8 million, up 14.7%; selling, general and administrative expense was $414.4 million, up 79.3%. Product gross margin was 71.8%, versus 75.8% in the prior-year period.
- Cash flow: Operating activities used $295.2 million in the first half, compared with $604.9 million used a year earlier. Investing activities provided $543.5 million, largely reflecting net sales and maturities of investments; financing activities provided $143.1 million.
- Liquidity and debt: At June 30, cash, cash equivalents and restricted cash totaled $1.79 billion; short-term investments were $2.61 billion. Total debt was $629.7 million, including $434.8 million classified as short-term. Total assets were $5.52 billion and accumulated deficit was $3.97 billion.
Material changes and management outlook
- Product revenue growth reflected higher sales of tislelizumab and BRUKINSA, plus sales of XGEVA and newly launched pamiparib. NRDL inclusion increased demand for tislelizumab, BRUKINSA and XGEVA but also reduced prices; distributor compensation for pre-NRDL inventory affected first-half revenue and margins.
- Management expected 2021 product revenue growth, driven by launch-related volume gains, and expected gross margin to normalize in the remainder of the year as sales mix evolved. These are expectations, not guarantees.
- The $650 million Novartis upfront payment supported collaboration revenue: the license allocation was recognized in the first half, while the R&D-services allocation is recognized as work is performed. Up to $1.3 billion in regulatory milestones, $250 million in sales milestones and future royalties remain contingent.
- Management expected continued losses and rising near-term spending, particularly for R&D, manufacturing and commercialization. It stated that existing cash, cash equivalents and short-term investments were expected to fund operations and capital needs for at least 12 months after issuance of the financial statements, while noting that further financing might be needed for broader development and launch plans.
- ABRAXANE remained unavailable in China following the NMPA suspension and recall; the company could not predict when sales could resume. BeiGene is pursuing arbitration against Celgene/BMS over supply obligations; the counterclaim seeks approximately $17 million, and a hearing was scheduled for June 2022.
- Commitments included $909.8 million remaining under the Amgen co-development funding cap, $220.1 million of purchase commitments, $70.7 million of capital commitments and $74.8 million of R&D commitments. The STAR Market offering had received listing committee approval but remained subject to additional approvals and market conditions.
Key risks and items to verify
- Verify product-level sales growth, NRDL price effects and rebate accruals, especially the $28.1 million first-half distributor adjustment.
- Track ABRAXANE supply restoration, the arbitration and the approximately $17 million counterclaim.
- Review short-term debt maturities and extensions, including the Senior Loan’s original October 2021 maturity and the related-party loan terms.
- Assess whether cash use, planned spending and contingent collaboration payments remain consistent with management’s stated liquidity runway.
- Monitor clinical and regulatory outcomes, reimbursement and competition, manufacturing capacity and third-party supply, COVID-19 effects, and China-related regulatory, data, currency and audit-inspection risks.
- Confirm the status and terms of the proposed STAR Market offering and any resulting dilution or additional compliance obligations.